Greek pharma boss: ‘We reached our limits, our sustainability is at stake’

By |december 4th, 2018|drug pricing, Greek crisis, News|

The Greek pharmaceutical industry has reached its limits due to a number of “unreasonable” burdens imposed by the government during the crisis, Greek pharma chief Olympios Papadimitriou told EURACTIV.com in an interview. The sustainability of pharma companies is at stake, threatening 86,000 jobs, he said.

Komentarji so izklopljeni za Greek pharma boss: ‘We reached our limits, our sustainability is at stake’

The European Commission should shelve its patent law proposal

By |november 30th, 2018|drug approval, drug innovation, drug pricing, News, patent, SPC manufacturing waiver|

The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.

Komentarji so izklopljeni za The European Commission should shelve its patent law proposal

Greek minister: Effective health and pharma policy needs stronger EU Commission role

By |november 7th, 2018|drug innovation, drug pricing, Greek austerity, Greek crisis, News|

A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.

Komentarji so izklopljeni za Greek minister: Effective health and pharma policy needs stronger EU Commission role

New drugs: how much are governments paying for innovation?

By |oktober 10th, 2018|drug innovation, drug pricing, generic drugs, News, Orphan drugs|

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.

Komentarji so izklopljeni za New drugs: how much are governments paying for innovation?

Investment in digital health and access to drugs at the core of Austrian Presidency

By |julij 10th, 2018|access to medicine, Clemens Martin Auer, drug pricing, early market authorisation, European Health Forum Gastein, Health Technology Assessment, News|

Austria’s EU Presidency will focus on “strong” investment in digital health as well as on regulatory issues when it comes to access to medicines, Dr Clemens Martin Auer told EURACTIV.com in an interview. Dr Clemens Martin Auer is the president of the...

Komentarji so izklopljeni za Investment in digital health and access to drugs at the core of Austrian Presidency

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

By |julij 3rd, 2018|Big pharma, drug innovation, drug pricing, EFPIA, generic drugs, intellectual property rights, News, Orphan drugs, pharmaceutical companies, SPC manufacturing waiver|

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  

Komentarji so izklopljeni za EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

Expert: Drug remuneration based on outcome should include distributors

By |junij 14th, 2018|drug pricing, healthcare access, News, Smart Healthcare|

The adoption of an outcome-based approach regarding the remuneration of medicines should take into account the entire chain, including the distributors, René Jenny, President of the European Healthcare Distribution Association (GIRP), told EURACTIV.com.

Komentarji so izklopljeni za Expert: Drug remuneration based on outcome should include distributors

Time to end fragmentation of EU healthcare, experts say

By |maj 8th, 2018|Celgene, drug innovation, drug pricing, EFPIA, News|

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.

Komentarji so izklopljeni za Time to end fragmentation of EU healthcare, experts say

Greek business chief: Novartis scandal must be dealt with quickly to avoid ‘social eruption’

By |februar 26th, 2018|drug pricing, Greek austerity, Greek bailout, Greek crisis, Konstantinos Michalos, News|

The Novartis scandal in Greece exists and the people responsible for it should be dealt with quickly in order to avoid a “social eruption”, Greek business leader Konstantinos Michalos told EURACTIV.com in an interview.

Komentarji so izklopljeni za Greek business chief: Novartis scandal must be dealt with quickly to avoid ‘social eruption’

Greek politicians face probe in pharma bribery scandal

By |februar 22nd, 2018|Alexis Tsipras, bribery, drug pricing, News, novartis scandal|

The Greek parliament decided on 21 February to establish a special committee that will investigate the role of politicians in the alleged Novartis scandal, a case that analysts claim will shake up the country’s political system.

Komentarji so izklopljeni za Greek politicians face probe in pharma bribery scandal